Involvement of IgG Derived from Cancer in Tumor Immune Escape (P2147)

Xiaoyan Qiu,Wenwei Shao,Lin Xiao,Guohui Li,Jing Huang,Ning Fu
DOI: https://doi.org/10.4049/jimmunol.190.supp.170.30
2013-01-01
Abstract:As we known that IgG have served as prototypical effector molecules of immune defense. However, monomeric IgG, such as the IVIG purified from the serum of thousands of healthy donors, has been demonstrated as an immune inhibitor at high doses as a commonly administered for the treatment of a number of autoimmune diseases. Igs has long been considered to be only produced by B cells, however, by a series of experimental evidences from ours and others, it has been found that other types of non-hematopoietic cells, especially cancer cells could also produce IgG, and the IgG is involved in the cell survival and carcinogenesis. In this study, we unexpectedly found that like the IVIG, epithelial cancer-derived IgG, but not the normal IgG, also showed strong immune inhibitory effect to CD4+ or CD8+ T lymphocytes at low dose. More importantly, the inhibitory effect of cancer-derived IgG was stronger than IVIG. Subsequently, we have analyzed the mechanism of the immune inhibition. Our results suggested that cancer-derived IgG can not directly inhibit the activation and proliferation of CD4+ or CD8+ T cells, their immune inhibitory effect should be dependent on myeloid cells, at least partly, dependent on the monocytes. In addition, we found that the immune inhibitory effect of cancer-derived IgG was not dependent on the Treg. Although the mechanism is remain unclear, we believe that the IgG is so far unknown arms of tumor cells to against the immune system for their immune escape.
What problem does this paper attempt to address?